Related Experiment Video
Updated: Jun 8, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet therapy in acute coronary syndromes
Krishna G Aragam1, Deepak L Bhatt
1University of Michigan, Ann Arbor, MI, USA.
Insights
This review covers antiplatelet therapies for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). It discusses aspirin, adenosine diphosphate (ADP)-receptor blockers, glycoprotein IIb/IIIa inhibitors, and adherence issues.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antiplatelet therapy is crucial for managing acute coronary syndromes (ACS).
- It is also vital for preventing thrombotic complications during percutaneous coronary intervention (PCI).
Purpose of the Study:
- To review commonly used antiplatelet agents in ACS therapy.
- To discuss recent data on novel antiplatelet and antithrombin agents.
- To address challenges related to adherence to antiplatelet regimens.
Main Methods:
- Literature review of antiplatelet agents.
- Analysis of recent clinical data on novel therapies.
- Discussion of adherence factors.
Main Results:
- Aspirin, adenosine diphosphate (ADP)-receptor blockers, and glycoprotein IIb/IIIa inhibitors are key agents.
- Emerging data on novel ADP-receptor blockers and thrombin inhibitors are presented.
- Adherence to antiplatelet therapy is a significant clinical consideration.
Conclusions:
- Effective antiplatelet strategies are essential for ACS and PCI management.
- Understanding current and novel agents is critical for optimal patient care.
- Addressing adherence is necessary to maximize therapeutic benefits.
Abstract:
Antiplatelet therapy is integral to the acute and long-term management of acute coronary syndromes (ACSs) and for minimizing the thrombotic complications of percutaneous coronary intervention (PCI). This article reviews the most commonly used antiplatelet agents in ACS therapy--aspirin, adenosine diphosphate (ADP)-receptor blockers, and glycoprotein IIb/IIIa inhibitors. More recent data are also reviewed on novel ADP-receptor blockers and thrombin inhibitors before addressing issues of adherence to antiplatelet regimens.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations